September 11, 2006 – The FDA refused to approve Avastin from Genentech for breast cancer until it does additional work on its clinical data; an FDA staff memo claims Factive from Oscient Pharma causes skin infections; Cortex Pharma has responded to the FDA hold on its Ampakine compound; Somaxon finished its genotoxiticy studies of Silenor, a prospective insomnia drug; Codexis reached a development milestone in its research partnership with Schering-Plough; BioMarin Pharma presented positive preclinical results from a test of a drug for phenylketonuria; Digene touted its DNA test for the HPV virus; QLT will spend $104 million to buy 13 million shares of its common stock at $8 each; and Cipher said that its formulation of the pain killer tramadol failed a Phase III trial. The Centient Biotech 200™ was off by 24 points at 3683.85, a drop of .65%. More details...
